THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.***, you should at once hand this circular as well as relevant form of proxy to the purchaser or transferee, or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

(1) 2024 WORK REPORT OF THE BOARD
(2) 2024 WORK REPORT OF THE BOARD OF SUPERVISORS
(3) 2024 ANNUAL REPORT
(4) 2024 INDEPENDENT AUDITOR'S REPORT
(5) 2025 FINANCIAL BUDGET PLAN
(6) REPORTS ON REMUNERATION OF DIRECTORS AND SUPERVISORS FOR 2024 AND 2025
(7) RE-APPOINTMENT OF AUDITOR FOR 2025
(8) PROPOSED ANNUAL PROFIT DISTRIBUTION PLAN
(9) RE-ELECTION OF DIRECTORS
(10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
(11) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR SHAREHOLDER'S GENERAL MEETINGS
AND
NOTICE OF THE 2024 AGM

A letter from the Board is set out on pages 3 to 11 of this circular.

The Company intends to convene the 2024 AGM at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC. The notice of the 2024 AGM is set out on pages 16 to 18 of this circular.

Enclosed herewith is a form of proxy for use at the 2024 AGM, and such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.scientechmed.com).

If you intend to appoint a proxy to attend the 2024 AGM, you are required to complete the enclosed form of proxy in accordance with the instructions printed thereon and return the same. Shareholders should return the form of proxy to the H Share Registrar, in any event served by hand, by post or by fax not less than 24 hours before the time designated for holding the 2024 AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the 2024 AGM or any adjournment thereof should you so wish.

Reference to dates and times in this circular are to Hong Kong dates and time.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

April 17, 2025

CONTENTS

Page

In this circular, unless the context otherwise requires, the following expressions have the meanings set forth below:

"2024 AGM"	the 2024 annual general meeting of the Company to be convened by the Company at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC, or any adjournment thereof
"Announcement"	the announcement of the Company dated March 28, 2025 on proposed amendments to the Articles of Association
"Articles of Association"	the Articles of Association of the Company, as amended, modified or otherwise supplemented from time to time
"Audit Committee"	the audit committee of the Company
"Board"	the board of directors of the Company
"Board of Supervisors"	the board of supervisors of the Company
"China" or "PRC"	the People's Republic of China, excluding, for the purposes of this circular only, Hong Kong, Macau and Taiwan unless the context otherwise requires
"Company"	LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司), a joint stock limited liability company established in the PRC on January 29, 2021 and whose Shares are listed on the Main Board of the Stock Exchange
"Director(s)"	the director(s) of the Company
"H Share Registrar"	Tricor Investor Services Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Latest Practicable Date"	April 16, 2025, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange

"Main Board"	the Main Board of the Stock Exchange
"RMB"	Renminbi, the lawful currency of the PRC
"Rules of Procedure for Shareholder's General Meetings"	the Rules of Procedure for Shareholder's General Meetings of the Company
"Share(s)"	ordinary share(s) in the share capital of the Company with the par value of RMB1.00 each
"Shareholder(s)"	holder(s) of Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Supervisor(s)"	the supervisor(s) of the Company
"%"	per cent

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*
樂普心泰醫療科技（上海）股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2291)

Executive Directors:
Ms. Chen Juan *(Chairman)*

Non-executive Directors:
Ms. Zhang Yuxin
Mr. Fu Shan
Mr. Zhu Guanfu

Independent non-executive Directors:
Ms. Chan Ka Lai Vanessa
Mr. Zheng Yufeng
Mr. Zheng Junwei

Registered office:
Room 201, Building 41
No. 258, Xinzhuan Road
Songjiang District, Shanghai
the PRC

Head office in the PRC:
1/F, 5/F, Building 41
No. 258, Xinzhuan Road
Songjiang District, Shanghai
the PRC

Principal Place of Business in Hong Kong:
Room 1918, 19/F,
Lee Garden One,
33 Hysan Avenue,
Causeway Bay,
Hong Kong

April 17, 2025

To the Shareholders:

Dear Sir/Madam,

(1) 2024 WORK REPORT OF THE BOARD
(2) 2024 WORK REPORT OF THE BOARD OF SUPERVISORS
(3) 2024 ANNUAL REPORT
(4) 2024 INDEPENDENT AUDITOR'S REPORT
(5) 2025 FINANCIAL BUDGET PLAN
(6) REPORTS ON REMUNERATION OF DIRECTORS AND SUPERVISORS FOR 2024 AND 2025
(7) RE-APPOINTMENT OF AUDITOR FOR 2025
(8) PROPOSED ANNUAL PROFIT DISTRIBUTION PLAN
(9) RE-ELECTION OF DIRECTORS
(10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
(11) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR SHAREHOLDER'S GENERAL MEETINGS
AND
NOTICE OF THE 2024 AGM

I. INTRODUCTION

The purpose of this circular is to give you notice of the 2024 AGM and to provide you with further information in relation to the following resolutions to be proposed at the 2024 AGM to enable you to make an informed decision on whether to vote for or against or abstain from voting on the resolutions to be proposed at the 2024 AGM. Such resolutions and details are set out in this letter from the Board.

II. MATTERS TO BE CONSIDERED AT THE 2024 AGM

Ordinary Resolutions

1. 2024 Work Report of the Board

An ordinary resolution will be proposed at the 2024 AGM to approve the 2024 Work Report of the Board. The main content of the report is set out in the 2024 annual report published by the Company on the respective websites of the Company (www.scientechmed.com) and HKEXnews of the Stock Exchange (www.hkexnews.hk).

2. 2024 Work Report of the Board of Supervisors

An ordinary resolution will be proposed at the 2024 AGM to approve the 2024 Work Report of the Board of Supervisors. The main content of the report is set out in the 2024 annual report published by the Company on the respective websites of the Company and HKEXnews of the Stock Exchange.

3. 2024 Annual Report

An ordinary resolution will be proposed at the 2024 AGM to approve the 2024 Annual Report of the Company. The full text of the report is set out on the respective websites of the Company and HKEXnews of the Stock Exchange.

4. 2024 Independent Auditor's Report

An ordinary resolution will be proposed at the 2024 AGM to approve the 2024 Independent Auditor's Report. The full text of the report is set out in the 2024 annual report published by the Company on the websites of the Company and HKEXnews of the Stock Exchange.

5. 2025 Financial Budget Plan

An ordinary resolution will be proposed at the 2024 AGM to approve the 2025 Financial Budget Plan. In 2025, the Company plans to invest RMB120 million in research and development operations mainly on projects related to new products of occluder and heart valve, and spend RMB20 million on purchase of property, plant and equipment in 2025.

6. Report on Remuneration of Directors and Supervisors for 2024 and 2025

An ordinary resolution will be proposed at the 2024 AGM to approve the report on remuneration of Directors and Supervisors for 2024 and 2025. The Board and the Board of Supervisors are of the view that the report truthfully, accurately and completely reflected the remuneration of Directors and Supervisors in 2024 and the remuneration plan for 2025 is in line with the Company's actual remuneration policies.

Details about the remuneration of Directors and Supervisors are set out in the notes to the consolidated financial statements in the 2024 annual report published by the Company on the respective websites of the Company (www.scientechmed.com) and HKEXnews of the Stock Exchange (www.hkexnews.hk).

7. Re-appointment of Auditors for 2025

An ordinary resolution will be proposed at the 2024 AGM to approve the re-appointment of BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as the Company's auditor for the year 2025, until the conclusion of the 2025 annual general meeting of the Company, and to authorize the Board to determine its remuneration.

8. Proposed Profit Distribution Plan

The Board has resolved to recommend the payment of a final dividend of RMB0.62 per Share (tax inclusive) for the year ended December 31, 2024 (approximately RMB214.98 million in aggregate), which is subject to the approval by the Shareholders at the 2024 AGM, the final dividend will be paid in Hong Kong dollars except for the dividend to be distributed to the investors of Southbound Trading (as defined below). The exchange rate for the final dividend to be paid in Hong Kong dollars will be the mean of the exchange rates of Renminbi to Hong Kong dollars as announced by the People's Bank of China during the five business days preceding the date of approval of the final dividend at the 2024 AGM.

The final dividend is expected to be paid on or before Thursday, July 31, 2025 to the Shareholders whose names appear on the register of members of the Company on Friday, May 30, 2025.

To determine the entitlement of the Shareholders to receive the final dividend, the register of members of the Company will be closed from Wednesday, May 28, 2025 to Friday, May 30, 2025, both days inclusive. In order to qualify for the final dividend, all properly completed transfer forms accompanied by the relevant share certificates must be lodged with the branch share registrar of the Company in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on Tuesday, May 27, 2025 for registration. The record date for entitlement to the proposed final dividend is Friday, May 30, 2025.

An ordinary resolution will be proposed at the 2024 AGM to consider and approve the Proposed Annual Profit Distribution Plan.

Profit Distribution to Investors of Southbound Trading

For investors of the Shanghai Stock Exchange (including enterprises and individuals) investing in the H Shares of the Company listed on the Stock Exchange (the "Southbound Trading"), the Company will enter into the Agreement on Distribution of Cash Dividends of H Shares for Southbound Trading (《港股通H股股票現金紅利派發協議》) with the Shanghai Branch of China Securities Depository and Clearing Corporation Limited, pursuant to which, the Shanghai Branch of China Securities Depository and Clearing Corporation Limited, as the nominees of the H Shareholders for Southbound Trading, will receive all cash dividends distributed by the Company and distribute the cash dividends to the relevant investors of H Shares of Southbound Trading through its depositary and clearing system.

The cash dividends for the investors of H Shares of Southbound Trading will be paid in RMB. In accordance with the Notice on Tax Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shanghai and Hong Kong Stock Markets (Cai Shui [2014] No. 81) (《關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》 (財稅[2014]81號)) for dividends received by domestic investors from investing in H shares listed on the Stock Exchange through Southbound Trading, the company of such H Shares shall withhold and pay individual income tax at the rate of 20% on behalf of the investors. For dividends received by domestic securities investment funds from investing in H Shares listed on the Stock Exchange through Shanghai-Hong Kong Stock Connect, the tax payable shall be the same as that for individual investors. The company of such H Shares will not withhold and pay the income tax of dividends and bonuses for domestic enterprise investors and those domestic enterprise investors shall report and pay the relevant tax themselves.

The record date and the date of distribution of cash dividends and other arrangements for the investors of Southbound Trading will be the same as those for the H Shareholders.

Withholding and Payment of Final Dividends Income Tax

For individual H Shareholders whose country (region) of domicile is a country (region) which has entered into a tax treaty or tax arrangement with the PRC stipulating a tax rate of 10%, the Company will withhold and pay individual income tax at the rate of 10% on behalf of these individual H Shareholders in the distribution of the Final Dividends.

For individual H Shareholders whose country (region) of domicile is a country (region) which has entered into a tax treaty with the PRC stipulating a tax rate of less than 10%, the Company will temporarily withhold and pay individual income tax at the rate of 10% on behalf of these individual H Shareholders in the distribution of the Final Dividends.

For individual H Shareholders whose country (region) of domicile is a country (region) which has not entered into any tax treaties with the PRC, or under any other circumstances, the Company will withhold and pay individual income tax at the rate of 20% on behalf of these individual H Shareholders in the distribution of the Final Dividends.

According to the PRC Individual Income Tax Law, the PRC Regulations for Implementation of the Individual Income Tax Law and other relevant laws and regulations, the Company is required to withhold non-resident individual income tax for non-resident individual holders of H Shares. However, the Notice of the Ministry of Finance and the State Administration of Taxation on Certain Policies Regarding Individual Income Tax which has taken effect since May 13, 1994 grants an exemption to foreign individuals from PRC individual income tax on dividend from foreign-invested enterprises.

In accordance with the Notice on Tax Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shanghai and Hong Kong Stock Markets (Cai Shui [2014] No. 81) (《關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》 (財稅[2014]81號)) issued by the Ministry of Finance, the State Administration of Taxation and the China Securities Regulatory Commission, for dividends received by domestic investors from investing in H shares listed on the Stock Exchange through Shanghai-Hong Kong Stock Connect, the company of such H shares shall withhold and pay individual income tax at the rate of 20% on behalf of the investors. For dividends received by domestic securities investment funds from investing in H shares listed on the Stock Exchange through Shanghai-Hong Kong Stock Connect, the individual income tax shall be paid in accordance with the aforementioned regulations. For dividends received by domestic enterprise investors from investing in shares listed on the Stock Exchange through Shanghai-Hong Kong Stock Connect, the company of such H shares shall not withhold and pay the income tax for such dividends and those domestic enterprise investors shall report and pay the relevant tax on their own. Meanwhile, for the dividends obtained by domestic resident enterprises from holding relevant H shares for a consecutive 12 month period, the corporate income tax shall be exempted according to laws.

Shareholders are advised to consult their own tax advisers about the tax effect in China, Hong Kong and/or other countries (regions) in respect of owning and disposing of Shares if they are in any doubt as to the above arrangements.

Shareholders should read this paragraph carefully. Should there be anyone who intends to change his/her identity as a Shareholder, please seek advice on the relevant procedures from the nominees or trustees. The Company is neither obliged nor responsible for ascertaining the identities of the Shareholders. In addition, the Company will withhold corporate income tax and individual income tax in strict compliance with the relevant laws or regulations and the registered information on the H share register of members as at the dividend entitlement date, and will not entertain or assume responsibility for any requests or claims in relation to any delay or inaccuracies in ascertaining the identity of the Shareholders or any disputes over the arrangements for withholding the corporate income tax and individual income tax.

9. Proposed Re-Election of Directors

In accordance with Article 99 of the Articles, without violating the relevant laws, regulations and regulatory rules of a place where the Company' s shares are listed, a person newly appointed as director by the Board to fill a temporary vacancy or to add to the quota of directors of the Board shall serve until the next annual general meeting of the Company, at which time the said person is eligible for re-election. Accordingly, Mr. Zhu Guanfu and Mr. Zheng Junwei shall retire and, being eligible, have offered themselves for re-election as non-executive Director and independent non-executive Director, respectively, of the second section of the Board (collectively, the "**Proposed Re-election of Directors**").

In accordance with the Articles of Association, the above Proposed Re-election of Directors is subject to the approval of the Shareholders at the general meeting. The term of office of the re-elected Directors shall be effective upon consideration and approval thereof at the AGM, and their duties as Directors for the first session of the Board shall be removed accordingly. The Directors shall continue to perform their duties as Directors in accordance with applicable laws and regulations and the Articles of Association until the re-election of the members of the second session of the Board is complete. The term of office of the Directors of the second session will be three (3) years commencing from the conclusion of the AGM.

The Nomination Committee has reviewed the composition of the members of the Board and was of the view that the composition of the Board complies with the requirements of the Articles of Association (as amended by the Proposed Amendment to the Articles), the applicable laws, regulations, and the Listing Rules, and is consistent with the needs of the Company.

The Nomination Committee is of the opinion that Mr. Zheng Junwei demonstrate his ability to exercise independent judgment and to provide a balanced and objective view in relation to the Company's affairs. His educational and professional background has enabled him to provide relevant valuable insights and contribute to the diversity of the Board.

The Nomination Committee has assessed Mr. Zheng Junwei's confirmation of independence based on the independence criteria as set out in Rule 3.13 of the Listing Rules and is satisfied that he remains independent.

Subject to the approval of the Proposed Re-election of Directors at the AGM, the Company will enter into a letter of appointment with Mr. Zhu Guanfu and Mr. Zheng Junwei respectively.

Ordinary resolutions will be proposed at the AGM to consider and approve the above matters.

Information required to be disclosed under the Listing Rules in relation to the Proposed Re-election of Directors is set out in Appendix I to this Circular.

Special Resolutions

10. Proposed Amendments to the Articles of Association

As further mentioned in the Announcement, to allow (but not require) general meetings to be convened and held as hybrid or electronic meetings, the Board proposed to amend the Articles of Association (the "**Proposed Amendments to the Articles of Association**").

For details of the Proposed Amendments to the Articles of Association, please refer to the Appendix II to this Circular.

The Board considers that the Proposed Amendments to the Articles of Association are in the interests of the Company and the Shareholders as a whole.

The Proposed Amendments to the Articles of Association are subject to the approval of the Shareholders by way of special resolution at the 2024 AGM. The Proposed Amendments to the Articles of Association shall come into effect upon the passing of the relevant special resolution at the 2024 AGM. Prior to the passing of the relevant special resolution at the 2024 AGM, the prevailing Articles of Association shall remain valid.

The Articles of Association are prepared and written in Chinese without formal English version. As such, any English translation shall be for reference only. In the event of any inconsistency, the Chinese version shall prevail. After the Proposed Amendments to the Articles of Association come into effect, the full text of the revised Articles of Association will be published on the websites of the Stock Exchange and the Company.

11. Proposed Amendments to the Rules of Procedure for Shareholder's General Meetings

In view of the Proposed Amendments to the Articles of Association to allow (but not require) general meetings to be convened and held as hybrid or electronic meetings, the Board of Directors proposed to amend the Rules of Procedure for Shareholder's General Meetings accordingly (the "**Proposed Amendments to the Rules of Procedure for Shareholder's General meetings**").

For details of the Proposed Amendments to the Rules of Procedure for Shareholder's General Meetings please refer to Appendix III to this Circular.

The Board considers that the Proposed Amendments to the Rules of Procedure for Shareholder's General Meeting are in the interests of the Company and the Shareholders as a whole.

The Proposed Amendments to the Rules of Procedure for Shareholder's General Meeting are subject to the approval of the Shareholders by way of special resolution at the 2024 AGM. The Proposed Amendments to the Rules of Procedure for Shareholder's General Meeting shall come into effect upon the passing of the relevant special resolution at the 2024 AGM. Prior to the passing of the relevant special resolution at the 2024 AGM, the prevailing to the Rules of Procedure for Shareholder's General Meeting shall remain valid.

The Rules of Procedure for Shareholder's General Meeting are prepared and written in Chinese without formal English version. As such, any English translation shall be for reference only. In the event of any inconsistency, the Chinese version shall prevail.

III. 2024 AGM AND VOTING METHOD

The Company intends to convene the 2024 AGM at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC, to consider and, if appropriate, approve the matters set out in the notice of the 2024 AGM. The form of proxy has been sent to the Shareholders in accordance with the Listing Rules on April 17, 2025. The notice of the 2024 AGM is set out on pages 16 to 18 of this circular.

If you intend to appoint a proxy to attend the 2024 AGM, you are required to complete the enclosed form of proxy in accordance with the instructions printed thereon and return the same. The form of proxy should be returned to the H Share Registrar, in any event served by hand, by post or by fax not less than 24 hours before the time designated for holding the 2024 AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the 2024 AGM or any adjournment thereof should you so wish.

According to the Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution which relates purely to a procedural or administrative matter to be voted by a show of hands. Therefore, the chairman of the 2024 AGM will demand a poll for each resolution of the 2024 AGM in accordance with Article 89 of the Articles of Association.

On a poll, each Shareholder (or, if the Shareholder is a company, its duly authorized representative) who attends the 2024 AGM in person or by proxy may have one vote for each Share registered in its name in the register of members of the Company. Shareholders entitled to more than one vote need not use all their voting rights or use all their voting rights in the same way.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, no Shareholders shall abstain from voting at the 2024 AGM as at the Latest Practicable Date.

IV. CLOSURE OF REGISTER OF MEMBERS

To determine the list of Shareholders entitled to attend the 2024 AGM, the register of members of the Company will be closed from Monday, May 19, 2025 to Thursday, May 22, 2025 (both days inclusive), during which no transfer of Shares will be effected. Shareholders whose names appear on the Company's register of members on Thursday, May 22, 2025 shall be entitled to attend and vote at the 2024 AGM. To be eligible to attend and vote at the 2024 AGM, all transfer documents shall be delivered, no later than 4:30 p.m. on Friday, May 16, 2025, to the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

V. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VI. RECOMMENDATIONS

The Board (including independent non-executive Directors) are of the view that each of the ordinary resolutions and special resolutions set out in the notice of the 2024 AGM is in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend Shareholders to vote in favor of all resolutions to be proposed at the 2024 AGM.

Yours faithfully,
By Order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

NON-EXECUTIVE DIRECTOR

Mr. Zhu Guanfu, aged 42, is the non-executive Director since December 9, 2024 and has been the southern region sales director for coronary artery medical device of Lepu Medical Technology (Beijing) Co., Ltd.# (樂普(北京)醫療器械股份有限公司) ("**Lepu Medical**") since November 2020. From October 2015 to June 2023, he served as a provincial manager of pharmaceuticals, regional manager of pharmaceuticals, the southern region sales director for pharmaceuticals of Lepu Medical.

Prior to joining Lepu Medical, Mr. Zhu was the pharmaceutical sales representative of Merck (China) Co., Ltd. (默沙東(中國)有限公司) from May 2007 to December 2009. After that, Mr. Zhu worked as a senior sales representative at Merck Serono Co., Ltd. (默克雪蘭諾有限公司) from January 2010 to March 2013. He was also a regional sales manager of Rotam Reddy Pharmaceutical Co., Ltd. (龍燈瑞迪製藥有限公司) from April 2013 to March 2015 and a regional sales manager of Sanofi (China) Pharmaceutical Co., Ltd. (賽諾菲(中國)製藥有限公司) from March 2015 to August 2015.

Mr. Zhu graduated from the Guangzhou University of Chinese Medicine (廣州中醫藥大學) in July 2007 with a bachelor's degree in Chinese Medicine.

As at the Latest Practicable Date, Mr. Zhu is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above and as at the Latest Practicable Date, Mr. Zhu (i) did not hold any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, (ii) did not have any other major appointments and professional qualifications, and (iii) does not have any other relationships with any other Directors, senior management, substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Mr. Zhu will not receive any Director's emolument from the Company.

Save as disclosed above, there is no information in relation to the appointment of Mr. Zhu as a Director that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Zheng Junwei, aged 45, is the independent non-executive Director since July 26, 2024. Before joining our Company, Mr. Zheng has been committed to promoting the investment in China and international cooperation by enterprises of China Association of Enterprises with Foreign Investment (中國外商投資企業協會) ("**CAEFI**") members since he became the vice president of CAEFI since 2017. Since September 2018, Mr. Zheng initiated and organized 12 enterprises of CAEFI members engaging in biotechnology innovation to establish the CAEFI Biotechnology Innovation Working Committee Innovation Committee (生物科技創新工作委員會) ("**BIC**") and has been serving as its chairman since then. In addition, Mr. Zheng served in the Special Commissioner's Office of the Ministry of Commerce in Fuzhou (商務部駐福州特派員辦事處) as office manager from 2004 to 2017.

Mr. Zheng graduated from the School of International Relations, National University of Defense Technology, PLA (中國人民解放軍國防科技大學國際關係學院) (formerly known as Nanjing Institute of International Relations (南京國際關係學院)) in July 2003 with a bachelor's degree in international economics.

As at the date of this circular, Mr. Zheng is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Zheng shall be entitled to an annual salary of RMB200,000, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Save as disclosed above, as at the date of this circular, Mr. Zheng has confirmed each of the matters as follows: (i) that he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) that he does not currently hold any other position with the Company or any of its subsidiaries; (iii) that he does not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) that he has confirmed his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (v) that he did not and does not have any past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as such term is defined in the Listing Rules) of the Company; (vi) that there are no other factors that may affect his independence at the time of his appointment; and (vii) does not have any interest in the shares or underlying shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no information in relation to the appointment of Mr. Zheng as a Director that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

The details of the Proposed Amendments are as follows (shown with strikethrough to denote text to be deleted and underline to denote text to be added):

Before amendment	After amendment
Article 62 The Company shall convene the shareholders' general meeting at the Company's domicile or at such other place as specified in the notice of general meeting. The shareholders' general meeting shall have a venue and be convened ~~in physical form~~. The Company will also provide the internet voting platform, for the purpose of providing convenience to shareholders attending the shareholders' general meeting. A shareholder who participates in shareholders' general meeting in the aforesaid manner shall be deemed to be present at the meeting.	**Article 62** The Company shall convene the shareholders' general meeting at the Company's domicile or at such other place as specified in the notice of general meeting. The shareholders' general meeting shall have a venue and be convened **<u>on site, by video, by telephone conference and/or in other forms permitted by laws and regulations and the regulatory rules of place where the shares of the Company are listed.</u>** The Company will also provide the internet voting platform, for the purpose of providing convenience to shareholders attending the shareholders' general meeting. A shareholder who participates in shareholders' general meeting in the aforesaid manner shall be deemed to be present at the meeting.

The details of the Proposed Amendments are as follows (shown with strikethrough to denote text to be deleted and underline to denote text to be added):

Before amendment	After amendment
Article 11 The Company shall convene the shareholders' general meeting at the Company's domicile or at such other place as specified in the notice of general meeting. The shareholders' general meeting shall have a venue and be convened in physical form.	**Article 11** The Company shall convene the shareholders' general meeting at the Company's domicile or at such other place as specified in the notice of shareholders' general meeting. The shareholders' general meeting shall have a venue and be convened **on site, by video, by telephone conference and/or in other forms permitted by laws and regulations and the regulatory rules of place where the shares of the Company are listed.**

LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

NOTICE OF THE 2024 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2024 annual general meeting (the "**2024 AGM**") of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the "**Company**") will be held at 10:30 a.m. on Thursday, May 22, 2025 at Conference Room, 5/F, Building 41, No. 258, Xinzhuan Road, Songjiang District, Shanghai, the PRC, to consider and, if appropriate, approve, with or without amendments, the following resolutions. Unless otherwise specified, capitalized terms used in this notice shall have the same meanings as defined in the circular of the Company dated April 17, 2025 (the "**Circular**").

ORDINARY RESOLUTIONS

(1) To consider and approve the 2024 work report of the Board;

(2) To consider and approve the 2024 work report of the Board of Supervisors;

(3) To consider and approve the 2024 annual report;

(4) To consider and approve the 2024 independent auditor's report;

(5) To consider and approve the 2025 financial budget plan;

(6) To consider and approve the reports on remuneration of Directors and Supervisors for 2024 and 2025;

(7) To consider and approve the re-appointment of BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as the Company's auditor for 2025, until the conclusion of the 2025 annual general meeting of the Company, and to authorize the Board to determine its remuneration;

(8) To consider and approve the profit distribution plan of the Company for the year of 2024;

(9) To consider and approve the re-election of:

(a) Mr. Zhu Guanfu as a non-executive Director of the second session of the Board;

(b) Mr. Zheng Junwei as an independent non-executive Director of the second session of the Board;

SPECIAL RESOLUTIONS

(10) To consider and approve the proposed amendments to the articles of association of the Company; and

(11) To consider and approve the proposed amendments to the rules of procedure for shareholder's general meetings of the Company.

Details of the above resolutions submitted to the 2024 AGM are set out in the Circular.

By Order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
April 17, 2025

As at the date of this notice, the Board comprises Ms. Chen Juan as an executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), and it is registered under its Chinese name and English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

Notes:

i. To determine the list of Shareholders entitled to attend the 2024 AGM, the register of members of the Company will be closed from Monday, May 19, 2025 to Thursday, May 22, 2025 (both days inclusive), during which no transfer of Shares will be effected. Shareholders whose names appear on the Company's register of members on Thursday, May 22, 2025 shall be entitled to attend and vote at the 2024 AGM. To be eligible to attend and vote at the 2024 AGM, all transfer documents shall be delivered, no later than 4:30 p.m. on Friday, May 16, 2025, to the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

ii. Each Shareholder entitled to attend and vote at the 2024 AGM may, by completing the form of proxy of the Company, appoint one or more proxies to attend and vote at the 2024 AGM on his/her/its behalf. A proxy need not be a Shareholder. With respect to any Shareholder who has appointed more than one proxy, such proxies may only exercise their voting rights in a poll.

iii. The form of proxy shall be signed by the appointer or his/her attorney duly authorized in writing or, in the case of a legal person, must be either executed under its common seal or under the hand of its director or attorney duly authorized.

iv. In order to be valid, the form of proxy must be deposited, at the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 24 hours prior to the holding of the 2024 AGM or any adjournment thereof. If the form of proxy is signed by another person under a power of attorney or other authorization documents given by the appointer, such power of attorney or other authorization documents shall be notarized. The notarized power of attorney or other authorization documents shall, together with the form of proxy, be deposited at the specified place at the time set out in such form of proxy. Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the 2024 AGM or any adjourned meetings should they so wish.

v. Shareholders shall produce their identity documents and supporting documents in respect of the Shares held when attending the 2024 AGM. If Shareholders appoint an authorized representative to attend the 2024 AGM, the authorized representative shall produce his/her identity documents and a notarially certified copy of the relevant authorization instrument signed by the board of directors or other authorized persons of the Shareholders or other notarially certified documents allowed by the Company. Proxies shall produce their identity documents and the form of proxy signed by the Shareholders or their authorized representative(s) when attending the 2024 AGM.

vi. The Company shall have the right to request the proxies attending the 2024 AGM on behalf of the Shareholders to produce their identity documents.

vii. In the case of joint Shareholders, the vote cast by the senior Shareholder, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholders, and for this purpose seniority shall be determined by the order in which the names of the relevant joint Shareholders stand on the register of members of the Company.

Pursuant to the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Therefore, the resolutions set out in the notice of the 2024 AGM will be taken by poll.

The H Share Registrar, Tricor Investor Services Limited, is located at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Tel: +852 2980 1333, Fax: +852 2810 8185.